In the past twelve months, regenerative medicine investments gained momentum, as new and promising clinical data got released. The momentum has been growing in recent years, enabling the cell therapy and genome editing sectors to evolve into a global industry.
In a recent post, we considered commercial entities supporting the development of induced pluripotent stem cell (iPSC) therapies. It is also important to consider the government and academic entities driving forward therapeutic progress with the cell type.
The primary non-commercial institutions working toward this goal are:
- RIKEN Center in Kobe, Japan
- Kyoto University in Kyoto, Japan
- California Institute for Regenerative Medicine (CIRM) in California, USA
Each of these important institutions and their contributions to the development of new iPSC therapies is explored in detail below.
July 14, 2015, COLOGNE, Germany—Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, announced today that it has signed an sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property to use human iPSCs, enabling Axiogenesis to develop cellular assays and models derived from stem cells for use in drug discovery and toxicity screening for its customers. This agreement strengthens Axiogenesis’ ability to offer the market freedom-to-operate with Axiogenesis’ proprietary iPSC-derived cells and tissues.
To create profitable products and services, stem cell industry executives need to stay informed about rapidly-evolving industry trends. For this reason, this post explores important trends, events, and metrics of importance within the induced pluripotent stem cell (iPSC) industry. It also considers geographical dominance within the industry.
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been commercialized in a number of different ways. iPSCs have been used as tools for drug development and discovery, for toxicology applications, in stem cell biobanking, in personalized medicine, and as research products. While each of these commercial applications is important, this post specifically considers the use of iPSCs as research products – meaning, tools that scientists use in their labs for research purposes and applications.
Specifically, this post explores the breakdown of induced pluripotent stem cells (iPSCs) research products, by category. This analysis is intended to direct the decision-making of research supply companies by indicating where there is high market demand at this time. (To learn about future directions for iPSCs, click here.)